Drug Shortages Update – Message from the Canadian Rheumatology Association
The Canadian Rheumatology Association (CRA) has been recently notified by members across the country of shortages in certain medications that are integral to patient care. The CRA has previously responded to alerts […]
Lancet Study: Vaccine Effectiveness Amongst Ontario Patients With Immune-Mediated Inflammatory Diseases
The full article is available here: The Lancet Rheumatology […]
Ontario Science Table Guidelines for COVID Treatments & Other Important Links
Please note the following important links: Ontario Science Table Guidelines for COVID Treatments: https://covid19-sciencetable.ca/sciencebrief/clinical-practice-guideline-summary-recommended-drugs-and-biologics-in-adult-patients-with-covid-19-version-10-0/ COVID Assessment Centres: https://covid-19.ontario.ca/covid-19-test-and-testing-location-information#getting-a-clinical-assessment List of Sites Distributing Paxlovid: List of sites distributing Paxlovid – 2022-02-14 (2) […]
Actemra (Tocilizumab) Update
Please see the most up to date information on Actemra shortages: Actemra Update […]
The Journal of Rheumatology – Board of Directors Position Available
The Journal of Rheumatology is actively seeking to fulfill an open position on its Board of Directors for election at their June 2022 Annual General Meeting. The deadline to apply is January 31, […]
Fourth Dose Boosters of COVID-19 Vaccine – Update
It was announced on January 13, 2022, that immunocompromised individuals may begin booking appointments to receive their 4th dose of the COVID-19 vaccine. Here is some information and resources for your reference: – […]
Updated MoH Guidelines – Booster Shots for Immunocompromised Patients After Primary Series
On December 14, 2021, the Ministry of Health published updated guidelines on COVID-19 Vaccine Third Dose Recommendations.Highlights of changes:•Immunocompromised individuals who are eligible for a three-dose primary series may receive a booster dose ≥6 months […]
CMAJ Article: Projected impact of biosimilar substitution policies on drug use and costs in Ontario
The full article may be viewed via this link: https://www.cmajopen.ca/content/9/4/E1055 […]
Long COVID Study – Brain and Cognition Discovery Foundation
The Brain and Cognition Discovery Foundation has announced an ongoing clinical study that may be of interest to patients you provide care for who are experiencing complications from COVID-19. More information is available […]
Updated Biosimilar Fact Sheet Reflecting ODB Formulary Changes Effective November 19, 2021
An updated version of the biosimilar fact sheet is available here: Nov 19 Biosimilar-Fact-Sheet […]
